biostudies-literatureUnknown30(12)Roviello G<h4>Importance</h4>Avelumab maintenance therapy improves survival in patients with advanced urothelial carcinoma who respond to first-line platinum-based chemotherapy. However, real-world evidence on its effectiveness and on the prognostic value of baseline clinical factors remains limited.<h4>Objective</h4>To evaluate the real-world effectiveness of Avelumab maintenance therapy and to identify baseline prognostic factors associated with clinical outcomes.<h4>Design</h4>Multicenter prospective observational study including a retrospective cohort of patients treated before study initiation.<h4>Setting</h4>Several Italian oncology centers participating between 2021 and 2023.<h4>Participants</h4>A total of 251 patients with advanced or metastatic urothelial carcinoma who received Avelumab maiThe oncologistoyaf388https://www.ebi.ac.uk/biostudies/studies/S-EPMC12680435biostudies-literatureReal-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).PMC12680435Maruzzo MMela MMRebuzzi SERoviello GGambale EVascotto IANasso CMaiorano BADe Gennaro Aquino IDoni LRametta AMercinelli CPillozzi SGalli LPuglisi SMessina MAntonuzzo LBimbatti DGiannatempo PFornarini GSalfi ACerbone LRossi VSoraru MMennitto AMessina CFanelli MRizzo MErbetta EScolari FOrlando VfalseReal-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).<h4>Importance</h4>Avelumab maintenance therapy improves survival in patients with advanced urothelial carcinoma who respond to first-line platinum-based chemotherapy. However, real-world evidence on its effectiveness and on the prognostic value of baseline clinical factors remains limited.<h4>Objective</h4>To evaluate the real-world effectiveness of Avelumab maintenance therapy and to identify baseline prognostic factors associated with clinical outcomes.<h4>Design</h4>Multicenter prospective observational study including a retrospective cohort of patients treated before study initiation.<h4>Setting</h4>Several Italian oncology centers participating between 2021 and 2023.<h4>Participants</h4>A total of 251 patients with advanced or metastatic urothelial carcinoma who received Avelumab mai2025-01-01T00:00:00Z2025 Dec2026-06-10T03:13:24.477Z2026-06-10T03:07:47.559ZS-EPMC126804354126448010.1093/oncolo/oyaf388